Zhang ADDIN EN.CITE Placebo/no -62.55 (-98.10, 2014 CKD Patients Allopurinol 6 354 177 MD Random SCr (μmol/L) treatment YES ADDIN EN.CITE Bose ADDIN EN.CITE 61 Patients with CKD or Placebo/no -0.40 (-0.80, 2014 Allopurinol SCr (mg/dL) 3 130 NA MD Random decreased kidney treatment 0.00) function Zhang ADDIN EN.CITE Placebo/no eGFR 2014 CKD Patients Allopurinol 2 184 96 MD Fixed 5.65 (1.88, 9.41) NO ADDIN treatment (ml/min/1.73m2) EN.CITE Bose ADDIN 61 EN.CITE (discordance in Patients with statistical CKD or Placebo/no 3.10 (-0.90, significance) 2014 Allopurinol eGFR (ml/min/1.73m2) 5 346 NA MD Random decreased kidney treatment 7.10) function Zhang NO ADDIN ADDIN EN.CITE EN.CITE Placebo/no End-stage renal 2014 CKD Patients Allopurinol 5 267 132 RR Fixed 0.30 (0.19, treatment disease
Zhang ADDIN EN.CITE 2014 CKD Patients Allopurinol Placebo/no treatment SCr (μmol/L) 6 354 177 MD Random -62.55 (-98.10, YES ADDIN EN.CITE 61 Bose ADDIN EN.CITE 2014 Patients with CKD or decreased kidney function Allopurinol Placebo/no treatment SCr (mg/dL) 3 130 NA MD Random -0.40 (-0.80, 0.00) Zhang ADDIN EN.CITE 2014 CKD Patients Allopurinol Placebo/no treatment eGFR (ml/min/1.73m2) 2 184 96 MD Fixed 5.65 (1.88, 9.41) NO ADDIN EN.CITE 61 (discordance in statistical significance) Bose ADDIN EN.CITE 2014 Patients with CKD or decreased kidney function Allopurinol Placebo/no treatment eGFR (ml/min/1.73m2) 5 346 NA MD Random 3.10 (-0.90, 7.10) Zhang ADDIN EN.CITE 2014 CKD Patients Allopurinol Placebo/no treatment End-stage renal disease 5 267 132 RR Fixed 0.30 (0.19, NO ADDIN EN.CITE
Supplementary%20material_v7%20-%20Final-2.docx